After graduating from the University of Pune, India, A/Prof Khot trained in Internal Medicine in India and the UK, where he qualified as a Member of the Royal College of Physicians. He completed training in laboratory and clinical Haematology in London, UK, obtaining a Fellowship from the Royal College of Pathologists. This was followed by a clinical research fellowship involving early phase clinical trials in cell therapies and myeloma at the Peter MacCallum Cancer Centre. A/Prof Khot has published in international journals and presented in international conferences in his fields of interest of cell therapies, haematopoietic progenitor cell transplantation, myeloma and early phase clinical trials. He currently works as a Consultant Haematologist at the Peter MacCallum Cancer Centre and Bendigo Health and is an investigator in clinical trials involving novel agents in myeloma and advanced haematologic malignancies.
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia; Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, et al. Mol Ther. 2013 Jul 8.
Panobinostat in lymphoid and myeloid malignancies; Khot A, Dickinson M, Prince HM. Expert Opin Investig Drugs. 2013 Jul 3
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Blood. 2011, 24;118(22):5799-802.
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation; Khot A, Dickinson M, Stokes K, Harrison S, Burbury K, Fleming S, Wall D, Gambell P, Prince HM, Seymour JF, Ritchie D.; Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):42-7.
A Phase 1, Open-Label, Dose Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Intravenously Administered CX-5461 In Patients With Advanced Haematologic Malignancies.
Open-Label, Multi-Center, Randomized Study Of Anti-CCR4 Monoclonal Antibody KW-0761 Mogamulizumab) Versus Vorinostat In Subjects With Previously Treated Cutaneous T-Cell Lymphoma (CTCL).